Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GGNBP2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GGNBP2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GGNBP2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GGNBP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GGNBP2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GGNBP2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GGNBP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000193324 | Oral cavity | EOLP | negative regulation of protein phosphorylation | 82/2218 | 342/18723 | 2.24e-10 | 2.20e-08 | 82 |
GO:003367323 | Oral cavity | EOLP | negative regulation of kinase activity | 62/2218 | 237/18723 | 9.46e-10 | 6.75e-08 | 62 |
GO:000646922 | Oral cavity | EOLP | negative regulation of protein kinase activity | 56/2218 | 212/18723 | 4.15e-09 | 2.41e-07 | 56 |
GO:000189023 | Oral cavity | EOLP | placenta development | 39/2218 | 144/18723 | 4.49e-07 | 1.25e-05 | 39 |
GO:000189222 | Oral cavity | EOLP | embryonic placenta development | 26/2218 | 82/18723 | 1.50e-06 | 3.55e-05 | 26 |
GO:000170123 | Oral cavity | EOLP | in utero embryonic development | 72/2218 | 367/18723 | 1.02e-05 | 1.83e-04 | 72 |
GO:006145824 | Oral cavity | EOLP | reproductive system development | 81/2218 | 427/18723 | 1.09e-05 | 1.93e-04 | 81 |
GO:004860823 | Oral cavity | EOLP | reproductive structure development | 80/2218 | 424/18723 | 1.51e-05 | 2.50e-04 | 80 |
GO:00507321 | Oral cavity | EOLP | negative regulation of peptidyl-tyrosine phosphorylation | 19/2218 | 59/18723 | 2.95e-05 | 4.24e-04 | 19 |
GO:006109912 | Oral cavity | EOLP | negative regulation of protein tyrosine kinase activity | 12/2218 | 31/18723 | 1.19e-04 | 1.33e-03 | 12 |
GO:003313511 | Oral cavity | EOLP | regulation of peptidyl-serine phosphorylation | 33/2218 | 144/18723 | 1.33e-04 | 1.46e-03 | 33 |
GO:00182121 | Oral cavity | EOLP | peptidyl-tyrosine modification | 65/2218 | 378/18723 | 1.25e-03 | 9.02e-03 | 65 |
GO:006071121 | Oral cavity | EOLP | labyrinthine layer development | 13/2218 | 44/18723 | 1.30e-03 | 9.21e-03 | 13 |
GO:00507301 | Oral cavity | EOLP | regulation of peptidyl-tyrosine phosphorylation | 48/2218 | 264/18723 | 1.61e-03 | 1.08e-02 | 48 |
GO:00181081 | Oral cavity | EOLP | peptidyl-tyrosine phosphorylation | 64/2218 | 375/18723 | 1.65e-03 | 1.09e-02 | 64 |
GO:0042532 | Oral cavity | EOLP | negative regulation of tyrosine phosphorylation of STAT protein | 7/2218 | 17/18723 | 2.14e-03 | 1.34e-02 | 7 |
GO:00606743 | Oral cavity | EOLP | placenta blood vessel development | 9/2218 | 30/18723 | 6.33e-03 | 3.13e-02 | 9 |
GO:00610971 | Oral cavity | EOLP | regulation of protein tyrosine kinase activity | 19/2218 | 90/18723 | 8.39e-03 | 3.91e-02 | 19 |
GO:000170124 | Skin | cSCC | in utero embryonic development | 150/4864 | 367/18723 | 2.47e-10 | 1.04e-08 | 150 |
GO:004593628 | Skin | cSCC | negative regulation of phosphate metabolic process | 160/4864 | 441/18723 | 8.89e-07 | 1.63e-05 | 160 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GGNBP2 | SNV | Missense_Mutation | novel | c.308N>C | p.Leu103Pro | p.L103P | Q9H3C7 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GGNBP2 | insertion | Frame_Shift_Ins | novel | c.1108_1109insCGCTAAGTTGCTTTAGTAAGTCTCACAGG | p.Gln370ProfsTer42 | p.Q370Pfs*42 | Q9H3C7 | protein_coding | | | TCGA-A2-A0YH-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
GGNBP2 | insertion | Nonsense_Mutation | novel | c.824_825insGCGTATGTTTTAAATGTGTGTATGGAGGCTTATTTTGGATGCTGTAGA | p.Ala275_Glu276insArgMetPheTerMetCysValTrpArgLeuIleLeuAspAlaValAsp | p.A275_E276insRMF*MCVWRLILDAVD | Q9H3C7 | protein_coding | | | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GGNBP2 | SNV | Missense_Mutation | novel | c.2077N>G | p.Thr693Ala | p.T693A | Q9H3C7 | protein_coding | tolerated_low_confidence(0.13) | benign(0.026) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GGNBP2 | SNV | Missense_Mutation | novel | c.259N>A | p.Val87Ile | p.V87I | Q9H3C7 | protein_coding | tolerated(0.19) | benign(0.003) | TCGA-DG-A2KJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
GGNBP2 | SNV | Missense_Mutation | novel | c.778N>T | p.His260Tyr | p.H260Y | Q9H3C7 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GGNBP2 | SNV | Missense_Mutation | novel | c.583G>C | p.Val195Leu | p.V195L | Q9H3C7 | protein_coding | tolerated(0.08) | benign(0.342) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
GGNBP2 | SNV | Missense_Mutation | novel | c.939C>G | p.Ile313Met | p.I313M | Q9H3C7 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
GGNBP2 | SNV | Missense_Mutation | novel | c.935N>A | p.Arg312Gln | p.R312Q | Q9H3C7 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
GGNBP2 | SNV | Missense_Mutation | novel | c.1134N>T | p.Lys378Asn | p.K378N | Q9H3C7 | protein_coding | tolerated(0.06) | probably_damaging(0.996) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |